Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: A meta-analysis

Radiotherapy and Oncology

Volumn 110, Issue 1, 2014, Pages 25-30

  Wang, Shenming ^a   Tu, Jian ^a   Wang, Siwen ^a   Huo, Zijun ^a   Lin, Ying ^a   Li, Xiaoxi ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Differentiated thyroid cancer; Recombinant human thyrotropin; Remnant ablation; Thyroid hormone withdrawal

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROID HORMONE; THYROTROPIN;

CANCER SURGERY; COMPARATIVE EFFECTIVENESS; DIFFERENTIATED THYROID CANCER; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THYROGLOBULIN BLOOD LEVEL; THYROIDECTOMY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; PROCEDURES; THYROID NEOPLASMS;

HUMANS; IODINE RADIOISOTOPES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN ALFA;

EID: 84896074615     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.12.018     Document Type: Article

References (28)

1. L. Wartofsky Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin Thyroid 12 2002 583 590 (Pubitemid 34815515)
2. A.M. Sawka, K thephamongkhol, M. Brouwers, L. Thabane, G. Browman, and H.C. Gerstein Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer J Clin Endocrinol Metab 89 2004 3668 3676 (Pubitemid 39089119)
3. M.J. Magarey, and J.L. Freeman Recurrent well-differentiated thyroid carcinoma Oral Oncol 49 2013 689 694
4. D.T. Woodrum, and P.G. Gauger Role of 131I in the treatment of well differentiated thyroid cancer J Surg Oncol 89 2005 114 121 (Pubitemid 40315907)
5. D.S. McLeod, A.M. Sawka, and D.S. Cooper Controversies in primary treatment of low-risk papillary thyroid cancer Lancet 381 2013 1046 1057
6. O. Husson, H.R. Haak, W.A. Oranje, F. Mols, P.H. Reemst, and L.V. van de Poll-Franse Health-related quality of life among thyroid cancer survivors: a systematic review Clin Endocrinol (Oxf) 75 2011 544 554
7. M.K. Chen, I. Doddamane, and D.W. Cheng Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management Curr Opin Oncol 22 2010 6 10
8. T.S. Wang, S.A. Roman, and J.A. Sosa Differentiated thyroid cancer: an update Curr Opin Oncol 23 2011 7 12
9. W.R. Burns, and M.A. Zeiger Differentiated thyroid cancer Semin Oncol 37 2010 557 566
10. J.P. Higgins, D.G. Altman, and P.C. Gotzsche et al the Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
11. M.G. Castagna, G. Cevenini, and A theodoropoulou et al. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients Eur J Endocrinol 169 2013 23 29
12. J.J. Ware, and C.D. Sherbourne The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med Care 30 1992 473 483
13. M. Schlumberger, B. Catargi, and I. Borget et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer N Engl J Med 366 2012 1663 1673
14. U. Mallick, C. Harmer, and B. Yap et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer N Engl J Med 366 2012 1674 1685
15. N. Emmanouilidis, J.A. Muller, and M.D. Jager et al. Surgery and radioablation therapy combined: introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSH Eur J Endocrinol 161 2009 763 769
16. F. Pacini, P.W. Ladenson, and M. Schlumberger et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study J Clin Endocrinol Metab 91 2006 926 932 (Pubitemid 43357760)
17. D. Taieb, F. Sebag, and M. Cherenko et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study Clin Endocrinol (Oxf) 71 2009 115 123
18. J. Lee, M.J. Yun, K.H. Nam, W.Y. Chung, E.Y. Soh, and C.S. Park Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma Thyroid 20 2010 173 179
19. M. Chianelli, V. Todino, and F.M. Graziano et al. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients Eur J Endocrinol 160 2009 431 436
20. A. Valachis, and A. Nearchou High versus low radioiodine activity in patients with differentiated thyroid cancer: a meta-analysis Acta Oncol 52 2013 1055 1061
21. W. Cheng, C. Ma, and H. Fu et al. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis J Clin Endocrinol Metab 98 2013 1353 1360
22. R.K. Grewal, S.M. Larson, and C.E. Pentlow et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation J Nucl Med 50 2009 1605 1610
23. N.G. Iyer, L.G. Morris, R.M. Tuttle, A.R. Shaha, and I. Ganly Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy Cancer 117 2011 4439 4446
24. S. Metso, A. Auvinen, H. Huhtala, J. Salmi, H. Oksala, and P. Jaatinen Increased cancer incidence after radioiodine treatment for hyperthyroidism Cancer 109 2007 1972 1979 (Pubitemid 46744190)
25. T.P. Links, and A.N. van der Horst-Schrivers Thyroid cancer: successful remnant ablation-what is success? Nat Rev Endocrinol 8 2012 514 515
26. M. Carballo, and R.M. Quiros To treat or not to treat: the role of adjuvant radioiodine therapy in thyroid cancer patients J Oncol 2012 2012 707156
27. C. Schvartz, F. Bonnetain, and S. Dabakuyo et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients J Clin Endocrinol Metab 97 2012 1526 1535
28. E.K. Alexander, and P.R. Larsen Radioiodine for thyroid cancer - is less more? N Engl J Med 366 2012 1732 1733